Online inquiry

IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6231MR)

This product GTTS-WQ6231MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets RABVgp4 gene. The antibody can be applied in Rabies research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NP_056796.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1489856
UniProt ID P08667
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6231MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4981MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ9786MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ9752MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ11222MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ389MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ13752MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ13751MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ11293MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-522
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW